The verdict of the investigation into the deal that would make Zimmer the world's second-largest seller of orthopaedic products behind allowed the merger to take place in June 2015. You get more revenue per that procedure. Zimmer Biomet supports a number of community-based educational, civic and cultural activities carried out by non-profit organizations. Next status conference set for May 21, 2015 at 9:30 a. Thanks for squeezing me in and really excited that the call had no drops so far. Bryan Hanson -- President and Chief Executive Officer Sure.
We also continue to meet our short-term operational goals on our roadmap to go on offense in the back half of the year. Just wondered if you can comment on that. And we've been a little more transparent here, obviously. Thank you very much for taking the question. The court, accordingly, gives the listed plaintiffs 30 days from the date of this order to show cause why their case should not be dismissed with prejudice.
So those are softer side of things, a little more subjective, but you can just feel it. Currently, Zimmer Biomet is concentrating on the priority areas like quality remediation, supply recovery, patientsafety, quality, integrityand product launches. Dan Florin -- Chief Financial Officer Kristen, it's Dan. See its 7 best stocks now. I truly believe that we have over 100 units placed around the globe, something like 140 units placed around the globe. It's that balanced selling that will really drive the durability of our overall growth.
And for whatever reason, that robotic system somehow gets unregistered with the patient, you put that screw in places you don't want it to go. We've talked a lot about this as an organization. So, I probably won't speak any more to it because I don't want to send any clear messages to my competition. So, it will be something that we concentrate on. So, best way to reach us is via email. Current faculty address fundamental questions in bioengineering, and optical biology, sensing, neurobiology, genetics, cardiovascular diseases, cellular signaling, and protein structure.
Second, we will establish Zimmer Biomet as a trusted partner with all of our stakeholders, including customers, regulators, team members, and investors. Our next question comes from Kyle Rose with Canaccord Genuity. Recon Market Steady Analysts are always reading the tea leaves of Biomet's reports because they are the first big ortho company to report sales. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. On a reported basis, knees and hips each rose 1%, spine increased by 4%, extremities gained 22% and trauma, excluding the acquisition, was flat. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
The resulting increase in scale, expansion of our product portfolio and infusion of talent will accelerate our efforts to be the partner of choice in spine for distributor partners, hospitals and the spine surgeons we serve. We have raw material increases every year and these projects need to begin to offset those first and then get after actual margin expansion. Steven Lichtman -- Oppenheimer and Company -- Analyst Thanks, guys. That's right -- they think these 10 stocks are even better buys. And then, secondly, the other major robotic player that's frequently talked about robots in a competitive account, presumably at 40% market share for Zimmer. Now, just to set the right expectations, this will take a while for those projects to get in to play, start to materialize and then capitalize into the gross margin impact that we have.
So, when you do hear our competitor talk about placing in competitive accounts, those are probably the types of accounts that they're talking about. And when that occurs, you get more share of wallet. It's not necessarily a surprise to us. Current appointments extended to December 31, 2013. The questions around that are, one, what's the status of the Sidus stemless shoulder rollout and what are your expectations for that business? I think, Dan, you committed to some level of margin expansion in 2020. And of course, actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties.
So, just I want to make sure you're not mistaking my enthusiasm for something that says we're going to change our guidance or we're going to change our view of the turnaround. The court, accordingly, affords the plaintiffs listed 30 days from the date of the order to show cause why their case should not be dismissed with prejudice. We're going to have a bunch of different things that will drive it. And I'm going to spend a little bit of time giving an update on each of these priorities. Thanks for taking the questions. And so, they found out that we have one unit that provides both the brain application as well a spine application, with small hardware changes and software changes, but one unit, it became very attractive to that individual. That is an annual headwind against gross margin.